Mary Moreland Sells 613 Shares of Abbott Laboratories (NYSE:ABT) Stock

Abbott Laboratories (NYSE:ABT) EVP Mary Moreland sold 613 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the transaction, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Abbott Laboratories Stock Down 0.5%

Shares of NYSE ABT traded down $0.57 during trading hours on Tuesday, hitting $113.55. 6,686,129 shares of the stock were exchanged, compared to its average volume of 9,201,159. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23. The firm has a fifty day moving average price of $116.90 and a 200-day moving average price of $125.00. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The company has a market cap of $197.31 billion, a PE ratio of 30.52, a PEG ratio of 1.82 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the business posted $1.34 EPS. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories’s payout ratio is 67.74%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Brighton Jones LLC grew its stake in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after acquiring an additional 4,755 shares during the period. Sivia Capital Partners LLC boosted its holdings in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after acquiring an additional 162 shares during the period. United Bank grew its holdings in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after purchasing an additional 2,001 shares in the last quarter. GHP Investment Advisors Inc. increased its position in shares of Abbott Laboratories by 0.8% during the second quarter. GHP Investment Advisors Inc. now owns 29,713 shares of the healthcare product maker’s stock worth $4,041,000 after acquiring an additional 222 shares during the last quarter. Finally, Versor Investments LP acquired a new position in shares of Abbott Laboratories in the 2nd quarter valued at approximately $408,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: FDA cleared Abbott’s redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader intended to improve patient convenience and clinical workflow. The approval, together with existing reimbursement for implantable PA sensors, could boost physician adoption and revenue potential in Abbott’s cardiac portfolio. Abbott wins FDA approval for updated heart failure monitoring device How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
• Neutral Sentiment: Analyst commentary highlights reasons to like Abbott’s durable device franchises and margin profile but reiterates skepticism after the recent softer quarter that contributed to underperformance versus the S&P over the past six months. This keeps sentiment mixed until revenue and growth re‑acceleration are clearer. 2 Reasons to Like ABT and 1 to Stay Skeptical
• Negative Sentiment: Clustered insider selling: multiple senior executives sold a combined ~3,055 shares on March 2 at about $115.58 per share (notable filings from VP John McCoy, EVPs Mary Moreland, Daniel Salvadori, Elizabeth Cushman and SVP Eric Shroff). While the executives retain large holdings, concentrated sales can pressure sentiment near the sale price. SEC Form 4 (John A. Jr. McCoy)
• Negative Sentiment: Market reaction/price momentum — coverage and market notes report ABT shares have recently pulled back (near the mid‑$110s) after the quarter, which is reinforcing selling pressure in the near term. Investors are watching upcoming catalysts and whether CardioMEMS adoption lifts growth enough to reverse the trend. Abbott (ABT) Stock Sinks As Market Gains: Here’s Why Abbott (ABT) Stock Sinks As Market Gains: Here’s Why (Zacks)

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ABT shares. Oppenheimer decreased their target price on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Royal Bank Of Canada dropped their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Sanford C. Bernstein reduced their target price on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. BTIG Research decreased their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Finally, Raymond James Financial lowered their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $137.05.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.